EP Patent

EP2621568B1 — Inhaler

Assigned to Novartis AG · Expires 2018-11-07 · 8y expired

What this patent protects

Patent listed against umeclidinium-bromide.

Drugs covered by this patent

umeclidinium-bromide (UMECLIDINIUM BROMIDE)

Patent Metadata

Patent number: EP2621568B1
Jurisdiction: EP
Classification: —
Expires: 2018-11-07
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.